Alumis reported a reduced net loss in Q3 2026 and reaffirmed its timeline for submitting an NDA for its lead psoriasis drug candidate, envudeucitinib. The company also announced plans for a new Phase 2 trial for A-005 in Parkinson's disease, indicating pipeline progression and a clear path for its lead asset.
Alumis Inc. reported a net loss of $94.9 million for Q3 2026, an improvement from $110.8 million in Q3 2025, signaling better financial management or reduced R&D burn. The company also reaffirmed its critical plan to submit a New Drug Application (NDA) for envudeucitinib for plaque psoriasis in Q4 2026, which is a major de-risking event for its lead candidate. Additionally, the announcement of a Phase 2 biomarker trial for A-005 in Parkinson's disease in 2027 indicates pipeline expansion and future growth potential. This news is positive for Alumis, as it demonstrates progress on its lead asset and a healthy cash runway into Q4 2027. For traders, the reaffirmed NDA submission is a key short-term catalyst, while the new trial offers long-term upside potential, reducing immediate funding concerns.